論文・技術情報追加のお知らせ

1. Potential adverse events associated with sphingosine-1-phosphate (S1P) receptor modulators in patients with multiple sclerosis: an analysis of the FDA adverse event reporting system (FAERS) database.

S1PRモジュレーターに関連する潜在的な有害事象と重要な医学的事象をFAERSで調査

対象DB：FAERS

2. Trust but Verify: Lessons Learned for the Application of AI to Case-Based Clinical Decision-Making From Postmarketing Drug Safety Assessment at the US Food and Drug Administration.

FDAはAIを用いて副作用の評価を改善しようとしているが、AIアルゴリズムの信頼性向上が課題

対象DB：FAERS

3. Safety evaluation of ceftazidime/avibactam based on FAERS database.

CZAの潜在的な副作用とリスクに注意が必要。胆汁うっ滞、薬物性肝障害、溶血性貧血、高ナトリウム血症、中毒性表皮壊死症など

対象DB：FAERS

4. Immune-related adverse events of immune checkpoint inhibitors combined with angiogenesis inhibitors: A real-world pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database (2014-2022).

ICIsとAGIsの組み合わせは、ICIs単独よりもirAEの発生率と死亡率を低下させる可能性

対象DB：FAERS

5. A pharmacovigilance study of drug-reduced male semen quality based on the Food and Drug Administration adverse event reporting system database.

男性精液の質を低下させる可能性のある薬剤のリスト

対象DB：FAERS

6. Cardiovascular events of Bruton's tyrosine kinase inhibitors: A real-world study based on the United States Food and Drug Administration Adverse Event Reporting System database.

BTKIの心血管有害事象、特にアカラブルチニブで新しいリスクが明らかに

対象DB：FAERS

7. Pediatric Drug-Induced Anaphylaxis Reports in the FDA Adverse Event Reporting System (FAERS).

抗体医薬品は小児のアナフィラキシーの主要原因に

対象DB：FAERS

8. Assessing the Impact of Morphine on Adverse Outcomes in ACS Patients Treated with P2Y12 Inhibitors: Insights from Multiple Real-World Evidence.

モルヒネとP2Y12阻害薬の相互作用が、腎障害および心筋梗塞リスク増加に関連

対象DB：FAERS

9. Safety and efficacy evaluation of Simo decoction and Arecae semen in herbal medicine practice.

四磨湯の有効性とリスク分析、特に発がん性リスクの評価が重要

対象DB：VigiBase

10. Propofol infusion syndrome: Analysis of French pharmacovigilance and World Health Organization Pharmacovigilance (VigiBase(R)) databases from 2020 to 2023.

プロポフォール乱用症候群の薬剤監視分析

対象DB：VigiBase

11. Use of methylphenidate and reporting of valvular heart disease: Global pharmacovigilance analysis in children and adults.

メチルフェニデートは成人で心臓弁膜症リスクを増加

対象DB：VigiBase

12. Trends in the surgical treatment for metastatic spinal tumor in Japanese administrative data between 2012 and 2020.

脊椎転移手術が増加し、入院死亡率と滞在期間は減少

対象DB：DPC

13. Thromboembolic events and vascular dementia in patients with atrial fibrillation and low apparent stroke risk.

AF患者はリスク因子なくても血栓と認知症リスク増

対象DB：CPRD

14. Safety and effectiveness of SGLT2 inhibitors in a UK population with type 2 diabetes and aged over 70 years: an instrumental variable approach.

70歳以上のSGLT2iは効果あり、感染とケトアシドーシスリスク増

対象DB：CPRD

15. Identifying subtypes of type 2 diabetes mellitus with machine learning: development, internal validation, prognostic validation and medication burden in linked electronic health records in 420 448 individuals.

機械学習で2型糖尿病を4つのサブタイプに分類

対象DB：CPRD

16. Prevalence, Incidence and Treatment Patterns of Prurigo Nodularis in England: A Retrospective Database Analysis.

中等度～重度のPN患者は治療薬の処方が多い傾向

対象DB：CPRD

17. Collateral effects of the COVID-19 pandemic on endocrine treatments for breast and prostate cancer in the UK: a cohort study.

COVID-19パンデミックで乳癌と前立腺癌患者の内分泌治療増加、骨関連合併症管理不足が判明

対象DB：CPRD